The following guideline can be ordered through the address listed in the "Source/Publisher"-category. In cases in which you can order through the Internet we have established a hyperlink.

Eudralex Volume 3 CHMP/CAT position statement on Creutzfeldt-Jakob disease and advanced therapy medicinal products


European Commission Enterprise and Industry DG, BREY 13/ 092, B - 1049 Brussels (Belgium),

Document Type:
Draft Guideline
The composition of ATMPs may include components of human origin (either as active ingredient, excipients, or raw materials used in their manufacture) and, therefore, the risk of transmitting CJD or vCJD agents has to be considered. Current status of related guidelines

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information